Last reviewed · How we verify
Cyanamid (CALCIUM CARBIMIDE)
Cyanamid (generic name: CALCIUM CARBIMIDE) is a calcium carbimide drug. It is currently in Phase 2 development.
Calcium carbimide works by inhibiting the activity of certain enzymes involved in cellular processes.
Cyanamid is a small molecule compound with the synonyms Calcium Carbimide, Calcium Carbimide, Calcium Cyanamide, and others. It is a calcium salt of cyanamide.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CALCIUM CARBIMIDE |
|---|---|
| Drug class | calcium carbimide |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like factories that use enzymes to get things done. Calcium carbimide is like a tool that blocks some of these enzymes, which can help slow down or stop certain processes in the body. This can be useful in treating certain conditions, but more research is needed to understand how it works and its potential side effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyanamid CI brief — competitive landscape report
- Cyanamid updates RSS · CI watch RSS
Frequently asked questions about Cyanamid
What is Cyanamid?
How does Cyanamid work?
What is the generic name of Cyanamid?
What drug class is Cyanamid in?
What development phase is Cyanamid in?
Related
- Drug class: All calcium carbimide drugs
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing